Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:56 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 524 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Kidney Transplant; Complications Clear all

Conditions: Glomerulonephritis
Interventions: LNP023; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Clostridium Difficile Infection, Recurrent Clostridium Difficile Infection, C. Diff, CDI, Recurrent C. Diff, rCDI, C. Difficile, Recurrent CDI, FMT, Fecal Microbiota, Fecal Transplant
Interventions: CP101; Biological
Lead sponsor: Finch Research and Development LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 53
States / cities: Scottsdale, Arizona • Los Angeles, California • Murrieta, California + 47 more

Conditions: End-stage Kidney Disease
Interventions: Inform Me: web-based education tool; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 21 Years and older
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 2
States / cities: Birmingham, Alabama • Chicago, Illinois

Conditions: Kidney Transplantation
Interventions: Arm 1: SOC (mTOR + CNI), Arm 2A: TRACT/MONO mTOR, Arm 2B: TRACT/MONO CNI; Drug · Biological
Lead sponsor: Singulera Therapeutics Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 3
States / cities: Phoenix, Arizona • Chicago, Illinois • Rochester, Minnesota

Conditions: Osteoporosis, Renal Osteodystrophy, Kidney Transplant; Complications
Interventions: Denosumab Inj 60 mg/ml, Placebo; Drug · Other
Lead sponsor: Thomas Nickolas, MD MS; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 3
States / cities: Chicago, Illinois • Evanston, Illinois • New York, New York

Conditions: Stenosis of Vascular Prosthetic Devices, Implants and Grafts
Interventions: FLAIR Endovascular Stent Graft, PTA; Device · Procedure
Lead sponsor: C. R. Bard; Industry
Eligibility: 21 Years and older
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Bamberg, South Carolina

Conditions: Focal Segmental Glomerulosclerosis
Interventions: Rituximab, Plasmapheresis; Drug · Procedure
Lead sponsor: University of Minnesota; Other
Eligibility: 1 Year to 65 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 12
States / cities: Tuscaloosa, Alabama • Davis, California • Chicago, Illinois + 8 more

Conditions: Kidney Transplantation, End Stage Renal Disease
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 8,951 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 3
States / cities: Birmingham, Alabama • Minneapolis, Minnesota • Rochester, Minnesota

Conditions: Kidney Transplant Rejection
Interventions: AT-1501, Tacrolimus; Drug
Lead sponsor: Eledon Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 27
States / cities: Los Angeles, California • Orange, California • Sacramento, California + 23 more

Conditions: Kidney Failure, Chronic
Interventions: Prehabilitation; Other
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Lutherville, Maryland

Conditions: Transplant Complication, CMV
Interventions: Maribavir, Valganciclovir; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndrome, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma, Multiple Myeloma, Waldenstrom Macroglobulinemia, Breast Cancer, Renal Cell Carcinoma, Melanoma, Sarcoma, Ovarian Cancer, Thymoma
Interventions: Nonmyeloablative Allogeneic Transplant; Procedure
Lead sponsor: Scripps Health; Other
Eligibility: 18 Years to 72 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2015
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Kidney Disease, Liver Disease, Pancreas Disease
Interventions: RIPC by Inflation of Pneumatic Tourniquet; Procedure
Lead sponsor: University of Medicine and Dentistry of New Jersey; Other
Eligibility: 5 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Renal Failure
Interventions: Group 1: Alternative Fistula, Group 2: Forearm AV Graft; Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Cytomegalovirus, Organ Transplant, Kidney Transplant; Complications, Liver Transplant Complications, Simultaneous Liver-Kidney Transplantation; Complications
Interventions: Cytomegalovirus Immune Globulin Intravenous (Human) monthly for three months; Drug
Lead sponsor: Camille N. Kotton, MD; Other
Eligibility: 18 Years to 75 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Boston, Massachusetts • Dallas, Texas

Conditions: Focal Segmental Glomerulosclerosis
Interventions: LIPOSORBER® LA-15 System; Device
Lead sponsor: Kaneka Medical America LLC; Industry
Eligibility: Up to 21 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2029
U.S. locations: 12
States / cities: Loma Linda, California • Los Angeles, California • Wilmington, Delaware + 9 more

Conditions: End Stage Renal Disease
Interventions: Expedial Vascular Access Graft; Device
Lead sponsor: LeMaitre Vascular; Industry
Eligibility: 18 Years and older
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 8
States / cities: Miami, Florida • Baton Rouge, Louisiana • The Bronx, New York + 4 more

Conditions: Focal Segmental Glomerulosclerosis, Minimal Change Disease, FSGS, MCD
Interventions: Biospecimen collection, Data collection; Other
Lead sponsor: University of Michigan; Other
Eligibility: Not listed
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Renal Failure
Interventions: Not listed
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 797 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Cancer
Interventions: methotrexate, methylprednisolone, prednisone; Drug
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Not listed
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Kidney Disease
Interventions: donor bone marrow infusion; Procedure
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: Not listed
Healthy volunteers: Accepts healthy volunteers
Timeline: 1998 – 2003
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Renal Cell Carcinoma
Interventions: Donor Radical and Partial Nephrectomy, Kidney Transplantation, Laparoscopic Radical Nephrectomy; Procedure
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 60 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Chronic Kidney Disease (CKD)
Interventions: Noninterventional; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 9
States / cities: Los Angeles, California • Orange, California • San Francisco, California + 6 more

Conditions: Kidney Failure, Hepatitis C, Kidney Disease, Chronic
Interventions: Glecaprevir and Pibrentasvir; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Study on Efficacy and Safety of LNP023 in C3 Glomerulopathy Patients Transplanted and Not Transplanted

Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection

Optimizing Kidney Transplant Informed Consent

REgulatory T Cell Therapy to Achieve Immunosuppression REduction

The Effects of 12-months of Denosumab on Bone Density in Prevalent Kidney Transplant Recipients

Post-Approval Study for the FLAIR Endovascular Stent Graft

PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant

Live Kidney Donor Study

Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation

Prehabilitation for Adults With End Stage Renal Disease on the Kidney Transplant Waitlist

Maribavir vs. Valganciclovir for CMV Prophylaxis in High-Risk Kidney Transplant Recipients

Nonmyeloablative Allogeneic Transplant

Remote Ischemic Preconditioning In Abdominal Organ Transplantation

Randomized Fistula Study

Strategic Help With Immunoglobulin to Enhance Protect Against Late Disease (CMV)

Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children

Study to Evaluate the Performance and Safety of Expedial and Compare it to Expanded Polytetrafluoroethylene (ePTFE) Vascular Access Grafts

Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease

Dexmedetomidine and Renal Transplants

Methotrexate and Glucocorticoids in Treating Patients With Newly Diagnosed Acute Graft-Versus-Host Disease After Donor Stem Cell Transplant

Living-Related Donor Bone Marrow Immunoregulation in Kidney Transplants

Transplantation of Reconstructed Renal Allografts Following Ex-Vivo Partial Nephrectomy

An Observational Extension Study for Adult Patients Treated in Study R5459-RT-1944 Who Receive a Kidney Transplant

QUICKly Eradicate Hepatitis C in Patients Undergoing REnal Transplant With 4 Weeks of Glecaprevir/Pibrentasvir